111604-91-2

Upstream product

• 111604-85-4 [2-(5-trifluoromethyl-2-nitrophenyl)-1-(4-methoxyphenyl)ethyl]propanedioic acid,dimethyl ester 
• 67192-42-1 2-methyl-4-trifluoromethylnitrobenzene 
• 111604-90-1 [2-(5-trifluoromethyl-2-aminophenyl)-1-(4-methoxyphenyl)ethyl]propanedioic acid,dimethyl ester 
• 7443-25-6 dimethyl 2-(4-methoxybenzylidene)malonate 

Downstream Products

• 138337-25-4 (3S,4R-cis)-3-hydroxy-1-<2-(dimethylamino)ethyl>-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one 
• 138383-41-2 (cis)-3-(Hydroxy)-1-[2-(dimethylamino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one 
• 138335-38-3 cis-1,3,4,5-tetrahydro-7-(trifluoromethyl)-3-(acetylthio)-1-<2-(dimethylamino)ethyl>-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one 
• 138335-34-9 N-[(3S,4R)-1-(2-Dimethylamino-ethyl)-4-(4-methoxy-phenyl)-2-oxo-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl]-acetamide 
• 118262-72-9 1,3,4,5-tetrahydro-7-(trifluoromethyl)-3-<(tolylsulfonyl)oxy>-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one 
• 138335-18-9 Thioacetic acid S-[(3S,4R)-4-(4-methoxy-phenyl)-2-oxo-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl] ester 
• 138383-08-1 Acetic acid (3S,4R)-1-(2-dimethylamino-ethyl)-4-(4-methoxy-phenyl)-2-oxo-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl ester 
• 138337-25-4 cis-3-hydroxy-1-<2-(dimethylamino)ethyl>-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-7-(trifluoromethyl)-2H-1-benzazepin-2-one 
• 138335-08-7 (3R,4S)-3-Hydroxy-4-(4-methoxy-phenyl)-7-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 138335-10-1 (3S,4S)-3-Hydroxy-4-(4-methoxy-phenyl)-7-trifluoromethyl-1,3,4,5-tetrahydro-benzo[b]azepin-2-one 
• 118262-90-1 7-(trifluoromethyl)-1,3,4,5-tetrahydro-3-hydroxy-3-(methoxycarbonyl)-4-(4-methoxyphenyl)-2H-1-benzazepin-2-one 
• 118262-90-1 (3R,4R)-3-Hydroxy-4-(4-methoxy-phenyl)-2-oxo-7-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-3-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site

We have synthesized a series of benzazepinones (2) in order to determine the structure-activity relationships (SAR) for calcium channel blockers related to diltiazem. A prerequisite for calcium channel blocking activity in vitro and in vivo is the presenc

Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones

As part of a program to discover potent antihypertensive analogues of diltiazem (3a), we prepared 1-benzazepin-2-ones (4). Benzazepinones competitively displace radiolabeled diltiazem, and show the same absolute stereochemical preferences at the calcium channel receptor protein. Derivatives of 4 containing a trifluoromethyl substituent in the fused aromatic ring show potent and long-acting antihypertensive activity. Studies of the metabolism of 4 lead to the metabolically stable antihypertensive calcium channel blockers 5a and 5c. Benzazepinone 5a is a longer acting and more potent antihypertensive agent than the second generation diltiazem analogue TA-3090 (3e).